Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) EBT Margin (2016 - 2026)

Pharma-Bio Serv's EBT Margin history spans 16 years, with the latest figure at 1.59% for Q1 2026.

  • For Q1 2026, EBT Margin rose 120.0% year-over-year to 1.59%; the TTM value through Jan 2026 reached 0.76%, up 432.0%, while the annual FY2025 figure was 1.05%, 690.0% up from the prior year.
  • EBT Margin reached 1.59% in Q1 2026 per PBSV's latest filing, up from 0.2% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 13.57% in Q1 2023 to a low of 12.0% in Q3 2024.
  • Average EBT Margin over 5 years is 1.54%, with a median of 1.59% recorded in 2026.
  • The largest YoY upside for EBT Margin was 9068bps in 2022 against a maximum downside of -3976bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 4.98% in 2022, then crashed by -127bps to 1.33% in 2023, then skyrocketed by 52bps to 0.64% in 2024, then surged by 131bps to 0.2% in 2025, then surged by 703bps to 1.59% in 2026.
  • Per Business Quant, the three most recent readings for PBSV's EBT Margin are 1.59% (Q1 2026), 0.2% (Q4 2025), and 10.65% (Q3 2025).